Home Kallikreins as microRNA targets: an in silico and experimental-based analysis
Article
Licensed
Unlicensed Requires Authentication

Kallikreins as microRNA targets: an in silico and experimental-based analysis

  • Tsz-fung F. Chow , Megan Crow , Tammy Earle , Hala El-Said , Eleftherios P. Diamandis and George M. Yousef
Published/Copyright: May 15, 2008
Biological Chemistry
From the journal Volume 389 Issue 6

Abstract

microRNAs (miRNAs) are non-coding RNAs that target specific mRNAs. They have been shown to control many biological processes including cancer pathogenesis. Kallikreins (KLKs) are a family of serine proteases that are attracting interest as cancer biomarkers. The mechanism of regulation of kallikrein expression is largely unknown. We investigated the potential roles of miRNAs in regulating KLK expression. Using a bioinformatics approach, we identified 96 strong KLK/miRNA interactions. KLK10 is the most frequently targeted kallikrein, followed by KLK5 and KLK13. KLK1, KLK3, KLK8 and KLK12 do not have strongly predicted miRNA/KLK interactions. Ten miRNAs are predicted to target more than one KLK. KLK2, KLK4, KLK5 and KLK10 have multiple miRNA-targeting sites on their transcript. Chromosomes 19 and 14 harbor significantly more KLK-targeting miRNAs. Many KLK-targeting miRNAs have been shown to be dysregulated in malignancy. We experimentally verified our bioinformatics data for the let-7f miRNA in a cell line model. let-7f transfection led to a significant decrease in secreted KLK6 and KLK10 protein levels. Co-transfection of let-7f and anti-let-7f inhibitor was able to partially rescue these protein levels. We conclude that miRNAs play a role in the regulation of KLK expression. Further studies are needed to investigate whether this regulation is altered in cancer.


Corresponding author

Received: 2007-11-9
Accepted: 2008-1-7
Published Online: 2008-05-15
Published in Print: 2008-06-01

©2008 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Kallikreins and kallikrein-related peptidases
  3. Guest Editorial
  4. The 2nd International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2007) and the Commemorative Gold Medal of the E.K. Frey–E. Werle Foundation of the Henning L. Voigt Family
  5. Highlight: Kallikrein, kinins and kallikrein-related peptidases
  6. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
  7. Development of peptides specifically modulating the activity of KLK2 and KLK3
  8. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer
  9. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs)
  10. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions
  11. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology
  12. microRNAs: a new frontier in kallikrein research
  13. Functions of KLK4 and MMP-20 in dental enamel formation
  14. Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney
  15. Development of diabetic cardiomyopathy and the kallikrein-kinin system – new insights from B1 and B2 receptor signaling
  16. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor
  17. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model
  18. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia
  19. Kallikreins as microRNA targets: an in silico and experimental-based analysis
  20. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
  21. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids
  22. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells
  23. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells
  24. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines
  25. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung
Downloaded on 18.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/BC.2008.071/html
Scroll to top button